Drugs / ProBactrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00324532 | May 2006 → May 2007 | gastroesophageal reflux disease | BioBalance Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ProBactrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00324532 ↗ |
| Modality | Other / unclassified | “Probiotic E. Coli Strain M17” NCT00324532 ↗ |
| Route | Oral | “Each patient will then receive a daily intake of 30 mL two times daily, 30 minutes before meals” NCT00324532 ↗ |